Drug Type Small molecule drug |
Synonyms Amlodipine besylate/olmersartan medoxomil/rosuvastatin calcium, Amlodipine/olmesartan/rosuvastatin, Olmersartan medoxomil/amlodipine besilate/rosuvastatin calcium + [5] |
Target |
Action antagonists, inhibitors, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (27 Feb 2019), |
Regulation- |
Molecular FormulaC22H28CaFN3O6S |
InChIKeyAVDMILNVMOXCHF-DHMAKVBVSA-N |
CAS Registry147098-20-2 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Essential Hypertension | South Korea | 27 Feb 2019 | |
| Primary hypercholesterolemia | South Korea | 27 Feb 2019 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hyperlipidemias | Phase 3 | United States | 01 Jan 2017 | |
| Hypertension | Phase 3 | United States | 01 Jan 2017 |





